RAPT Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2021 – RAPT Therapeutics (Nasdaq: RAPT) announced that Brian Wong, M.D., Ph.D., President and CEO, will present at key investor conferences in September. Notably, he will speak at the Wells Fargo 2021 Virtual Healthcare Conference on September 9 at 8:00 a.m. EST and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. EST. For live webcasts and archived recordings, visit RAPT's official website. RAPT focuses on oral therapies for oncology and inflammatory diseases, advancing drug candidates targeting CCR4.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in the first half of September:

• Wells Fargo 2021 Virtual Healthcare Conference Thursday, September 9, 2021 at 8:00 a.m. EST
• H.C. Wainwright 23^rd Annual Global Investment Conference presentation available on-demand Monday, September 13, 2021 at 7:00 a.m. EST

To access the live webcasts or subsequent archived recordings of the company presentations, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com 

 

FAQ

What investor conferences will RAPT Therapeutics present at in September 2021?

RAPT Therapeutics will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

What time is the RAPT Therapeutics presentation at the Wells Fargo Conference?

The RAPT Therapeutics presentation at the Wells Fargo 2021 Virtual Healthcare Conference is scheduled for September 9, 2021, at 8:00 a.m. EST.

How can I access RAPT Therapeutics' conference presentations?

You can access RAPT Therapeutics' live webcasts and archived recordings of their conference presentations by visiting their official website.

What is the focus of RAPT Therapeutics' drug development?

RAPT Therapeutics focuses on discovering and developing oral small molecule therapies for significant unmet needs in oncology and inflammatory diseases.

What are the key drug candidates developed by RAPT Therapeutics?

RAPT Therapeutics has developed two key drug candidates: FLX475 and RPT193, targeting CCR4 for cancer and inflammation, respectively.